Top Medical News
3 days ago
Hair collar sign (HCS) and hair tuft of the scalp (HTS) may increase the risk for underlying neurovascular abnormalities in infants, suggests a recent study.
Jairia Dela Cruz, 7 days ago
Tranexamic acid shows potential in the treatment of melasma, demonstrating efficacy when used alone or in combination with other modalities while inducing relatively few side effects, according to a literature review.
7 days ago
Major depressive disorder (MDD) appears to contribute to a significant increase in the risk of developing psoriatic arthritis (PsA) among patients with psoriasis, a study suggests.
7 days ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
8 days ago
New drug applications approved by US FDA as of 1 - 15 March 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Audrey Abella, 12 days ago
Daptomycin is safe and effective for treating complicated skin and skin structure infections (cSSSI) in children compared with standard-of-care (SOC), a recent study has shown.
Stephen Padilla, 14 days ago
Maintenance with ixekizumab does not result in unexpected safety signals in patients with psoriasis, highlighting its acceptable safety profile, a recent study has found.
Special Reports
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
28 Nov 2016
During the 41st Annual Dermatology Conference held in Kuching, Sarawak, Professor Steven R. Feldman updated the participants on the latest in topical treatment of psoriasis. Highlights from the presentation are summarized below.
11 Nov 2016
At the 7th Galderma Skin Day, leading dermatologists, Dr Najeeb Ahmad Mohd Safdar of Hospital Tuanku Ja’afar, Seremban and Dr Derrick Aw of the National University Hospital, Singapore, presented on managing atopic dermatitis and hand eczema, with a special focus on Cetaphil® Restoraderm (Galderma) and the newly launched Nutraplus® (Galderma).
08 Nov 2016
At the 7th Galderma Skin Day, renowned dermatologists, Dr Derrick Aw of the National University Hospital, Singapore and Dr Chan Lee Chin of Penang Hospital, shared practice pearls on managing melasma and acne.
Dr. Ch’ng Chin Chwen, Prof. Maria Teresita Gabriel, 17 Oct 2016
A 42-year-old Pakistani female consulted for spontaneously occurring generalized wheals of 6 months duration. She noticed that the wheals mostly appeared on her upper body and were erythematous, painful, pruritic, and unsightly.
Prof. Maria Teresita Gabriel, 05 Aug 2016
A 66-year-old Filipino female dressmaker sought consult due to pruritus with the appearance of about less than 20 wheals on both of her forearms and wrists. This condition appeared 2 weeks prior to consult. There was no rapid swelling or angioedema noted and symptoms did not have a pattern.
Prof. Neal Bhatia, 05 Aug 2016
Although topical corticosteroids are effective for the treatment of seborrheic dermatitis, long-term use of these agents is limited by side effects. Moreover, increased understanding of the possible contribution of yeast species to the pathogenesis of the disease suggests that corticosteroids may also be limited by their lack of antifungal efficacy. By contrast, novel nonsteroidal treatments offer great promise. At the 2nd Asia Pacific Meeting of Experts in Dermatology (APMED) held recently in Hanoi, Vietnam, Associate Professor Neal Bhatia, from the Harbor-UCLA Medical Center, Los Angeles, California, US, discussed the potential benefits of new agents such as SebclairTM (Menarini), which combines anti-inflammatory and antifungal properties to effectively treat the symptoms of seborrheic dermatitis.
Conference Reports
Jackey Suen, 16 Feb 2017

Mortality rates of melanoma are predicted to fall by 2050, but the number of individuals dying from the disease will increase due to population growth and ageing.

Dr. Joseph Delano Fule Robles, 10 Feb 2017

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer. 

Christina Lau, 23 Dec 2016

Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.

Dr. Joseph Delano Fule Robles, 21 Dec 2016

Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL). 

Elaine Tan, 20 Oct 2016

Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.

Naomi Rodrig, 13 Oct 2016

Ipilimumab, given as adjuvant therapy after complete resection of stage III melanoma, significantly improved overall survival (OS) and distant metastases-free survival (DMFS) vs placebo, according to new results from the EORTC 18071 trial. [ESMO 2016, abstract LBA2_PR]

Stephen Padilla, 03 Oct 2016
The complex approach strategy, which includes educational programmes, reminding tips, and state-of-the-art therapy, may significantly increase patient adherence to antihypertensive treatment and improve blood pressure (BP) control in everyday routine practice, according to the PRISMA* study presented at the International Society of Hypertension (ISH) 2016 meeting in Seoul, Korea.